{
  "trial_id": "NCT04207593",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "WHO class I -IV (mPAP \u2265 25 mm Hg, pulmonary arterial occlusion pressure \u226415 mm Hg)",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "stable on optimized pharmacological treatment for at least six weeks",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "men and women 18 years of age or older",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "patient is diagnosed with Pulmonary Arterial Hypertension (World Health Organization (WHO) Category Group 1)",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "exclusion": [
    {
      "criterion": "patient has a stable functional class of PAH with no changes of medication during the trial",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "significant left heart disease, requiring acute pharmacological or interventional treatment",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "notes": "Patient has multifactorial chronic hypoxemia and dyspnea thought due to diastolic CHF, pulmonary hypertension thought secondary to a chronic ASD and COPD on 5L home oxygen. Cardiology consult recommended a right heart cath for evaluation of response to sildenafil but the patient refused.",
  "_meta": {
    "topic_id": "16",
    "trial_id": "NCT04207593",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}